Pfizer stock premarket refers to trading Pfizer shares (ticker: PFE) before regular market hours (9:30 AM - 4:00 PM ET). This session runs from 4:00 AM to 9:30 AM ET, letting investors react to overnight news.
Premarket trading operates like regular hours but with lower volume and volatility. Orders go through electronic communication networks (ECNs) that match buyers/sellers. Not all brokers offer premarket access, and liquidity is thinner.
For example, if Pfizer announces positive trial results for a new vaccine at 6:00 AM ET, traders might push the premarket price higher before the official open. The actual opening price may differ due to increased volume.
| Type | Example | Typical Impact |
|---|---|---|
| Earnings Reports | Pfizer's Q2 earnings released early | Price jumps if profits beat estimates |
| FDA Decisions | Approval for a new Pfizer drug | Sharp price increase on positive news |
| Global Events | COVID-19 variant outbreak | Volatility as traders assess impact |
Many assume premarket prices predict the regular session's direction. However, low liquidity can cause erratic moves that don't hold. For instance, Pfizer stock might gap up premarket on good news but fall during regular hours due to profit-taking.
Another myth is that premarket volume is insignificant. While lower than regular hours, it still averages 15-20% of daily volume for major stocks like Pfizer, according to NASDAQ data.
Premarket trading lacks market makers, reducing efficiency. Orders may take longer to fill, and spreads (difference between bid/ask) widen. For example, Pfizer's premarket spread might be $0.10 vs. $0.02 during regular hours.
Not all orders (like stop-losses) are supported premarket. Some brokers restrict advanced order types to regular hours only.
Premarket suits traders reacting to breaking news or positioning before the open. Investors should confirm orders execute at desired prices due to wider spreads. For long-term holders, buying Pfizer stock during regular hours often offers better execution.
I once watched Pfizer stock surge 3% premarket after an FDA advisory committee endorsed its COVID-19 vaccine. By the open, it had added another 2%. However, another time, a negative court ruling sent shares down 5% premarket, but they recovered slightly during the day.